PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Pathology and Translational Medicine10.4132/jptm.2021.10.15202256292-96An unusual case of microsatellite instability–high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencingBogyeong Han, Sehui Kim, Jiwon Koh, Jeong Mo Bae, Hongseok Yun, Yoon Kyung Jeonhttp://www.jpatholtm.org/upload/pdf/jptm-2021-10-15.pdf, http://www.jpatholtm.org/journal/view.php?doi=10.4132/jptm.2021.10.15, http://www.jpatholtm.org/upload/pdf/jptm-2021-10-15.pdf
Value in Health10.1016/j.jval.2018.09.135201821S22-S23PCN53 - STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORSM. Lorenzi, M. Amonkar, J. Zhang, S. Mehta, K. Liawhttps://api.elsevier.com/content/article/PII:S1098301518334351?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301518334351?httpAccept=text/plain
Value in Health10.1016/j.jval.2021.04.127202124S24PCN35 Systematic and Structured Reviews of the Disease Burden in Patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (DMMR) Colorectal Cancer (CRC)M. Amonkar, M. Chase, J. Takyar, S. Sharmahttps://api.elsevier.com/content/article/PII:S1098301521003442?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301521003442?httpAccept=text/plain
Journal of Oncology10.1155/2020/1807929202020201-17Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature ReviewMaria Lorenzi, Mayur Amonkar, Jacky Zhang, Shivani Mehta, Kai-Li Liawhttp://downloads.hindawi.com/journals/jo/2020/1807929.pdf, http://downloads.hindawi.com/journals/jo/2020/1807929.xml, http://downloads.hindawi.com/journals/jo/2020/1807929.pdf
Annals of Oncology10.1016/j.annonc.2020.08.1985202031S921-S9221479P Clinicopathological and genomic characteristics of DNA Mismatch Repair-Deficient (dMMR) and microsatellite instability-high (MSI-H) resected gastric adenocarcinomaJ. Zhou, B. Liang, M. Yin, H. Zhang, F. Liu, L. Dong, B. Zhang, Y. Xuhttps://api.elsevier.com/content/article/PII:S0923753420419817?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420419817?httpAccept=text/plain
Cancer10.1002/cncr.3179520181252278-289Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancerJacqueline N. Chu, Jin Choi, Sassan Ostvar, James A. Torchia, Kerry Lynn Reynolds, Angela Tramontano, Justin F. Gainor, Daniel C. Chung, Jeffrey W. Clark, Chin Hurhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.31795, http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31795/fullpdf
Value in Health10.1016/j.jval.2022.04.8472022257S452EPH95 Frequency of and Testing Patterns for Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (DMMR) Among Solid Tumors in a US Community Oncology SettingM Chase, A Vasudevan, M Amonkar, N Myer, T Wang, V Prabhu, V Turzhitsky, A Spirahttps://api.elsevier.com/content/article/PII:S1098301522010488?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301522010488?httpAccept=text/plain
Updates in Surgery10.1007/s13304-019-00697-2201972173-82Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment?Turan Acar, Nihan Acar, Erdinç Kamer, Mustafa Agah Tekindal, Fevzi Cengiz, Haldun Kar, Kemal Atahan, Mehmet Haciyanlihttp://link.springer.com/content/pdf/10.1007/s13304-019-00697-2.pdf, http://link.springer.com/article/10.1007/s13304-019-00697-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s13304-019-00697-2.pdf
Annals of Oncology10.1093/annonc/mdx422.001201728vi3Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 StudyS. Lonardi, T. Andre, K.Y.M. Wong, M. Morse, R. McDermott, A. Hill, A. Hendlisz, H. Lenz, J. Leach, R.A. Moss, Z.A. Cao, J. Ledeine, S. Kopetz, M. Overmanhttps://api.elsevier.com/content/article/PII:S092375342034672X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S092375342034672X?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_6/mdx422.001/21490335/mdx422.001.pdf
Annals of Oncology10.1016/j.annonc.2022.04.104202233S250P-12 A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HWT. André, E. Van Cutsem, E. Elez, J. Bennouna, C. de la Fouchardière, T. Yoshino, L. Jensen, G. Mendez, J. Li, E. Goekkurt, S. Abdullaev, T. Chen, M. Lei, S. Lonardihttps://api.elsevier.com/content/article/PII:S0923753422007943?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753422007943?httpAccept=text/plain